Ending the Epidemic Task Force Recommendation Form



COMPLETE

Collector: Web Link (Web Link)

Started: Tuesday, November 18, 2014 3:34:16 PM **Last Modified:** Tuesday, November 18, 2014 3:51:08 PM

Time Spent: 00:16:51 **IP Address:** 70.209.131.6

PAGE 1

Q1: OPTIONAL: This recommendation was submitted by (please provide your first and last name, affiliation, and email address)

First Name Gina

Last Name Quattrochi

Affiliation Bailey House and "30 for 30 Campaign"

Email Address Rqbh@ baileyhouse.org

Q2: Title of your recommendation Ensuring women's access to PrEP and PeP

Q3: Please provide a description of your proposed recommendation

PrEP and PeP education and drugs will be made available to women at women's reproductive health centers and abortion clinics.

Q4: For which goal outlined in the Governor's plan to end the epidemic in New York State does this recommendation apply? (Select all that apply)

Facilitating access to Pre-Exposure Prophylaxis (PrEP) for high-risk persons to keep them HIV negative

Q5: This recommendation should be considered by the following Ending the Epidemic Task Force Committee (Select all that apply)

Prevention Committee: Develop recommendations for ensuring the effective implementation of biomedical advances in the prevention of HIV, (such as the use of Truvada as pre-exposure prophylaxis (PrEP)); for ensuring access for those most in need to keep them negative; and for expansion of syringe exchange, expanded partner services, and streamlined HIV testing by further implementing the universal offer of HIV testing in primary care, among others. The Committee will focus on continuing innovative and comprehensive prevention and harm reduction services targeted at key high risk populations, as well as grantfunded services that engage in both secondary and primary prevention.

Q6: Does this recommendation require a change to an existing policy or program, or the creation of a new policy or program?

Unknown

Ending the Epidemic Task Force Recommendation Form

Q7: Would implementation of this recommendation be permitted under current laws or would a statutory change be required?	Permitted under current law
Q8: Is this recommendation something that could feasibly be implemented in the short-term (within the next year) or long-term (within the next three to six years)?	Within the next year

Q9: What are the perceived benefits of implementing this recommendation?

Women will have increased access to information about PrEP and PeP and the drugs that comprise these biomedical prevention interventions.

Q10: Are there any concerns with implementing this recommendation that should be considered?

None

Q11: What is the estimated cost of implementing this recommendation and how was this estimate calculated?

Funds would be provided to these clinics for educational materials and staff training.

Q12: What is the estimated return on investment (ROI) for this recommendation and how was the ROI calculated?

Decreased HIV incidence among women in NYS.

Q13: Who are the key individuals/stakeholders who would benefit from this recommendation?

Women, their families and the communities in which they reside.

Q14: Are there suggested measures to accompany this recommendation that would assist in monitoring its impact?

Require healthcare providers in these settings to document efforts at providing PrEP and PeP education and drugs to women seen in their clinics.

Q15: This recommendation was submitted by one of Ending the Epidemic Task Force member the following